Novel drug approvals via priority review pathway

The report stated that 17 among the 48 novel drugs received market approval through a priority review pathway, 11 gained conditional market approval and 13 were included in breakthrough therapy programs during clinical trials.

The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.

Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.

APA

National Medical Products Administration. (2024). China approves 48 innovative drugs in 2024. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm. Via StatOrigin, https://statorigin.org/stat/stat_7HAGBREDP4PN54PGTD9JEWGTR4

Copy

MLA

National Medical Products Administration. "China approves 48 innovative drugs in 2024." 2024, https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm. Accessed 17 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_7HAGBREDP4PN54PGTD9JEWGTR4.

Copy

Chicago

National Medical Products Administration. "China approves 48 innovative drugs in 2024." 2024. https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm. Accessed September 17, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_7HAGBREDP4PN54PGTD9JEWGTR4.

Copy

BibTeX

@misc{nmpa2024novelewgtr4, author = {{National Medical Products Administration}}, title = {China approves 48 innovative drugs in 2024}, year = {2024}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_7HAGBREDP4PN54PGTD9JEWGTR4}, note = {Original source: https://english.nmpa.gov.cn/2025-03/19/c\_1079532.htm. Accessed September 17, 2026.} }

Copy

Everything needed to check this number yourself, without taking our word for it.

Record last modified 17 September 2026. Value type: actual. Update cadence: annual. This page is permanently addressable at statorigin.org/stat/stat_7HAGBREDP4PN54PGTD9JEWGTR4.